ORIC Pharmaceuticals Analyst Price Targets

ORIC Pharmaceuticals Inc

ORICNASDAQ

Trade with Public

$12.72

0.373%

Últ. Act.: Oct 20, 4:07 AM

$12.90

0.554.45%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

ORIC Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for ORIC Pharmaceuticals (ORIC).

Price Target Range — 13 Quarters

Analyst Consensus — 17 Analysts

17Buy

Consensus RatingBuy# Analysts17Avg. Consensus PT$21Upside to Avg. PT+60.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 14, 2026	JP Morgan	Anupam Rama	PT Raise	Overweight	$23→$26
Oct 5, 2026	Leerink Partners	Asthika Goonewardene	Initiate	Outperform	$26
Sep 23, 2026	BTIG	Jeet Mukherjee	Initiate	Buy	$26
Aug 10, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$25→$27
Jun 8, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$25
May 15, 2026	Goldman Sachs	Corinne Johnson	Upgrade	Buy	$15
May 5, 2026	Citigroup	Yigal Nochomovitz	PT Cut	Buy	$17→$16
Apr 2, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$25
Apr 1, 2026	Wedbush	David Nierengarten	PT Cut	Outperform	$20→$17
Mar 13, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$25
Feb 24, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$16→$17
Feb 24, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$23→$25
Feb 24, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$20
Jan 13, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$20
Jan 7, 2026	Piper Sandler	Kelsey Goodwin	Initiate	Overweight	$22
Dec 8, 2025	Wells Fargo	Derek Archila	PT Raise	Overweight	$19→$25
Dec 8, 2025	Wedbush	David Nierengarten	Maintained	Outperform	$20
Nov 20, 2025	Evercore ISI Group	Cory Kasimov	Initiate	Outperform	$25
Nov 18, 2025	Wolfe Research	Kalpit Patel	Initiate	Peer Perform	—
Nov 18, 2025	JP Morgan	Anupam Rama	PT Raise	Overweight	$17→$20

More with Benzinga EdgeGet Access

Analyst Ratings News

Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Wednesday

Analysts raised targets for ACI, ORIC, JPM, SHOP, META and U; KTB upgraded to Buy. Domino’s target was cut.

Avi Kapoor

PRO
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and raises the price target from $23 to $26.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

Leerink Partners analyst Asthika Goonewardene initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform rating and announces Price Target of $26.

Benzinga Newsdesk

PRO
BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26

BTIG analyst Jeet Mukherjee initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and announces Price Target of $26.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27

HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $25 to $27.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and maintains $25 price target.

Benzinga Newsdesk

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Wednesday

PRO
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

PRO
Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

PRO
BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26

PRO
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27

PRO
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

ORIC Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Wednesday

PRO
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

PRO
Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

PRO
BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26

PRO
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27

PRO
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

People Also Watch

People Also Watch

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Wednesday

PROJP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

PROLeerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

PROBTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26

PROHC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27

PROHC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

ORIC Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Wednesday

PROJP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

PROLeerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

PROBTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26

PROHC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27

PROHC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

PRO
Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

PRO
BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26

PRO
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27

PRO
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target

PRO
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26

PRO
Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26

PRO
BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26

PRO
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27

PRO
HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target